# Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

> **NCT04761705** · PHASE1,PHASE2 · SUSPENDED · sponsor: **JeniVision, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Ocular Hypertension
- Open Angle Glaucoma

## Interventions

- **DRUG:** JV-GL1
- **DRUG:** Latanoprost 0.005% Ophthalmic Solution

## Key facts

- **NCT ID:** NCT04761705
- **Lead sponsor:** JeniVision, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-03-10
- **Primary completion:** 2025-03
- **Final completion:** 2025-07
- **Target enrollment:** 70 (ESTIMATED)
- **Why stopped:** Awaiting transition to Part 2
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04761705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04761705, "Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04761705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*